Specific protocols define eligibility, conditioning, donor selection, graft composition and
prophylaxis of graft vs. host disease for children and young adults undergoing hematopoietic …

Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better
outcome of hematopoietic stem cell transplantation (HSCT). Further improvement could be …

Busulfan (Bu) is a common component of conditioning regimens before hematopoietic stem
cell transplantation (HSCT) and is known for high interpatient pharmacokinetic (PK) …

Aims The aim of this study is to develop a population pharmacokinetic (PopPK) model for
intravenous busulfan in children that incorporates variants of GSTA1, gene coding for the main …

Hematopoietic stem cell transplantation (HSCT) is currently the standard of care for many
malignant and nonmalignant blood diseases. As several treatment-emerging acute toxicities …

Busulfan (Bu) is a key component of conditioning regimens used before hematopoietic stem
cell transplantation (SCT) in children. Different predictive methods have been used to …

Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication after
hematopoietic stem cell transplantation (HSCT) or antineoplastic treatment without HSCT. …

GSTA1 encodes a member of a family of enzymes that function to add glutathione to target
electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins, and …

Sinusoidal obstruction syndrome (SOS) is a well-recognized and potentially life-threatening
complication of hematopoietic stem cell transplantation (HSCT). SOS arises from endothelial …

Background Genotype-phenotype analyses of rare diseases often suffer from a lack of
power, due to small sample size, which makes identifying significant associations difficult. …